KalVista Pharmaceuticals (KALV) Share-based Compensation Growth (3y) (2019 - 2025)
KalVista Pharmaceuticals (KALV) Share-based Compensation Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 244.08% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -50.27% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -0.04% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 38.45% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -15.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -15.27% |
| Apr 30, 2025 | -14.73% |
| Oct 31, 2024 | -43.74% |
| Jul 31, 2024 | 2.84% |
| Apr 30, 2024 | 25.73% |
| Jan 31, 2024 | 29.75% |
| Oct 31, 2023 | 36.97% |
| Jul 31, 2023 | 39.92% |
| Apr 30, 2023 | 30.83% |
| Jan 31, 2023 | 77.64% |
| Jul 31, 2022 | 3.54% |
| Apr 30, 2022 | -101.67% |
| Jan 31, 2022 | 51.60% |
| Oct 31, 2021 | 43.10% |
| Jul 31, 2021 | 100.46% |
| Apr 30, 2021 | 57.94% |
| Jan 31, 2021 | 63.30% |
| Oct 31, 2020 | 65.97% |
| Jul 31, 2020 | 75.18% |
| Apr 30, 2020 | 87.26% |